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Background-—The association between pregnancy complications and women’s later cardiovascular disease has, primarily, been
evaluated in studies lacking information on important covariates. This report evaluates the prospective associations between
pregnancy-related risk factors (preeclampsia/eclampsia, gestational hypertension, pregestational and gestational diabetes
mellitus, preterm delivery, and fetal growth restriction) and pharmacologically treated hypertension within 10 years after
pregnancy, while adjusting for a wide range of covariates.
Methods and Results-—Prepregnancy normotensive women participating in the MoBa (Norwegian Mother and Child Cohort Study)
from January 2004 through July 2009 were linked to the Norwegian Prescription Database to identify women with
pharmacologically treated hypertension beyond the postpartum period of 3 months. The burden of hypertension associated
with pregnancy-related risk factors was evaluated using an attributable fraction method. A total of 1480 women developed
pharmacologically treated hypertension within the follow-up among 60 027 women (rate of hypertension, 3.6/1000 person-years).
The proportion of hypertension associated with a history of preeclampsia/eclampsia, gestational hypertension, preterm delivery,
and pregestational or gestational diabetes mellitus was 28.6% (95% confidence interval, 25.5%–31.6%) on the basis of multivariable
analyses adjusting for numerous covariates. The proportion was similar for women with a healthy prepregnancy body mass index
(18.5-24.9 kg/m2; attributable fraction (AF)% 25.9%; 95% confidence interval, 21.3%-30.3%), but considerably higher for nulliparous
women at baseline within the first 5 years of follow-up. Small-for-gestational age, however, did not increase subsequent
hypertension risk in multivariable analyses.
Conclusions-—A structured postpartum follow-up of high-risk women identified through pregnancy-related risk factors would
facilitate personalized preventive strategies to postpone or avoid onset of premature cardiovascular events. ( J Am Heart Assoc.
2018;7:e008318. DOI: 10.1161/JAHA.117.008318.)
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H ypertension is an important early detectable andmodifiable risk factor for cardiovascular disease
(CVD), and blood pressure–related disease is a major
contributor to the global burden of disability-adjusted life
years.1 De novo hypertensive disorders of pregnancy and
gestational diabetes mellitus (GDM) are recognized as risk
factors for premature maternal CVD.2 Evidence has also been
accumulating on maternal CVD associated with other preg-
nancy-related complications and outcomes,3 such as
preterm delivery,4–11 fetal growth restriction5,7,10,12 placental
abruption,13 and pregnancy losses.5,14–16
Most studies evaluating pregnancy-related outcomes for
their prediction of long-term maternal morbidity and mortality
have relied on large registry-based data sources that lack
From the Divisions of Health Data and Digitalization and Mental and Physical Health, Norwegian Institute of Public Health, Bergen and Oslo, Norway (G.M.E., S.S., A.-
K.D., K.K., L.T., P.M.M., A.L.B., M.H.); Department of Global Public Health and Primary Care, University of Bergen, Norway (G.M.E., G.E.E., A.-K.D., K.K.); Division of
Obstetrics and Gynaecology, Oslo University Hospital, Oslo, Norway (A.C.S.); Faculty of Medicine, University of Oslo, Norway (A.C.S.); and Centre for Clinical Research,
Haukeland University Hospital, Bergen, Norway (G.E.E.).
Accompanying Tables S1 through S4 are available at http://jaha.ahajournals.org/content/7/10/e008318/DC1/embed/inline-supplementary-material-1.pdf
Correspondence to: Grace M. Egeland, PhD, Norwegian Institute of Public Health, PO Box 973, Sentrum, N-5808 Bergen, Norway. E-mail: g.egeland@uib.no
Received December 22, 2017; accepted January 26, 2018.
ª 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons
Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-
commercial and no modifications or adaptations are made.
DOI: 10.1161/JAHA.117.008318 Journal of the American Heart Association 1
ORIGINAL RESEARCH






important information of risk factors that could contribute to
both adverse pregnancy-related outcomes and increased
lifetime risk of CVD. Preconception CVD risk factors, for
example, predicted preeclampsia/eclampsia (PE) and gesta-
tional hypertension (GH) in a prospective cohort,17 and
prepregnancy obesity is a known antecedent of many preg-
nancy-related complications.18 Furthermore, prepregnancy
maternal body mass index (BMI; kg/m2), blood pressure, and
lipid measurements accounted for a large percentage of the
postpregnancy differences in these risk factors between
women with and without PE/GH.19 Several recent studies,
however, have evaluated multiple relevant covariates in anal-
yses of the association between pregnancy-related events and
future maternal CVD end points.11,15,20–22 The multivariable
adjustment for numerous covariates has resulted in attenuation
in the measures of association with CVD outcomes. However,
there were persistent and significant predictions of later CVD
outcomes for PE,20 small-for-gestational age (SGA) infants,20
preterm delivery,11,20 pregnancy losses,15 and placental insuf-
ficiency disorders combined.21
Given the high percentage of women experiencing ≥1
adverse pregnancy events associated with maternal CVD, and
given that CVD remains a leading cause of morbidity and
mortality among women, better understanding of the impor-
tance of pregnancy events within context of a wide range of
other CVD risk factors is needed.
Therefore, the aim of the current study was to evaluate
pregnancy-related events for their association with subsequent
maternal hypertension development within 10 years after
delivery in analyses adjusting for numerous prepregnancy and
6-month postpartum risk factors for hypertension. Furthermore,
the proportion of risk of subsequent hypertension identified by
PE, GH, pregestational diabetesmellitus (DM) and GDM, preterm
delivery, and fetal growth restriction was evaluated.
Methods
Data related to the current study are not available to third
parties unless the data request meets the needs of specific
guidelines (E-mail: datatilgang@fhi.no for more information).
However, any details about methods or materials used to
conduct the research, not provided herein, are available on
request to the corresponding author.
Women from the MoBa (Norwegian Mother and Child
Cohort Study) were included in the current analyses. The
study is a prospective population-based pregnancy cohort
conducted by the Norwegian Institute of Public Health.23 The
current project was approved by the Regional Ethics Com-
mittee (Region West: 2013/740), and all participants gave
informed consent. Details of the study subset used in the
current analyses are reported elsewhere.24 In brief, pregnant
women were recruited from all regions in Norway, from 1999
to 2008, which included deliveries in 2009. Participation rate
was 41%, providing a sample size of 95 200 pregnant women.
Outcome
The outcome was pharmacologically treated hypertension in
mothers identified through the Norwegian Prescription
Database (2004–2013), hereafter referred to as subsequent
hypertension. Because the prescription database was estab-
lished in 2004,25 MoBa deliveries before 2004 were excluded
for the current analyses. Hypertension is defined as ≥140/
90 mm Hg measured at ≥2 physician visits.26,27 Antihyper-
tensive medications are recommended after a total evaluation
of blood pressure and concurrent disease and indicated if
systolic blood pressure is >160 mm Hg or diastolic blood
pressure is >100 mm Hg. Hypertension was considered
present if hypertension was listed as the underlying indication
for treatment for ≥1 of the Anatomical Therapeutic Chemical
(ATC) classification system dispensed prescriptions: antihy-
pertensives (ATC code: C02), diuretics (ATC code: C03), b
blockers (ATC code: C07), calcium channel blockers (ATC
code: CO8), and renin-angiotensin system medications (ATC
code: C09).28 If medication was used only during the
immediate postpartum period (<90 days from date of deliv-
ery), women were coded as nonhypertensive for analyses.
Covariates
The baseline lifestyle-related risk factors evaluated came
primarily from the first MoBa questionnaire administered in
Clinical Perspective
What Is New?
• Consideration of a wide range of covariates did not
appreciably alter the association of pregnancy-related risk
factors with risk of subsequent hypertension.
• A high population burden of hypertension (28.6%) was
attributed to pregnancy-related risk factors, including
preeclampsia/eclampsia, gestational hypertension, preterm
delivery, and pregestational or gestational diabetes mellitus.
• Findings were similar when limited to women with a normal
prepregnancy body mass index and stronger when limited to
nulliparous women at baseline with a follow-up limited to
the first 5 years.
What Are the Clinical Implications?
• Pregnancy-related complications can help identify women
early in the disease trajectory and help target monitoring
and interventions to women at risk.
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the second trimester (15–17 weeks) of pregnancy. Thematernal
prepregnancy lifestyle-related factors included education, daily
smoking, physical activity, and alcohol consumption frequency
in the past 3 months before pregnancy, and prepregnancy
height and weight for determining BMI. The baseline question-
naire also included questions of oral contraceptive use and
duration of use. At 6 months after delivery, another question-
naire ascertained breastfeeding, changes in weight from
prepregnancy weight, and smoking status. Dietary intake was
obtained from a semiquantitative food frequency questionnaire
developed specifically for the MoBa, and administered in the
22nd week of pregnancy.29 The MoBa food frequency question-
naire has been validated in substudies using a 4-day weighted
food diary, motion sensors, and biological markers.30,31 A poor
diet quality indicator variable was created on the basis of having
a high sodium/potassium ratio (top quartile, ≥0.88) or a low
dietary calcium or low magnesium intake (<736 or <310 mg/d,
respectively) given the available evidence of their importance in
hypertension.32–34 Low intake of calcium and magnesium and a
high ratio of sodium/potassium associated with hypertension
development in the current cohort of women.24 The extent of
missing data was low for most parameters (0%–3.2%), with the
exception of the 6-month postpartum data on weight gain
(17.9%), breastfeeding (14.3%), and smoking (20%).
The Medical Birth Registry of Norway (MBRN)35 was used to
identify PE (new-onset hypertension and proteinuria at >20
gestational weeks, as in the previous American College of
Obstetricians and Gynecologists’ criteria),36,37 GH (new-onset
hypertension diagnosed at >20 gestational weeks without
proteinuria), preterm delivery (<37 weeks), very preterm deliv-
ery (<32 weeks), DM, GDM, birth weight for gestational age and
sex,38 multiple birth pregnancies, parity (0, 1, and ≥2), and
maternal age at time of delivery. Given the small numbers with
DM and GDM, these 2 conditions were combined (DM/GDM).
A total of 62 746 mothers were identified who delivered
from January 2004 through July 2009, of whom 21%
participated in MoBa for >1 pregnancy. Women who had
hypertension before pregnancy or who had an early fetal loss
(<22 weeks) (n=1414), or women who reported unrealistically
high (>4400 kcal/d) or low (<1070 kcal/d) energy intakes,
were excluded (n=1305),29 leaving 60 027 women for the
analyses. If women participated more than once in MoBa, only
information from the last pregnancy was used in the current
analyses. By using the last pregnancy in MoBa, we avoided
methodological problems associated with changing status
over time in exclusion criteria and in important covariates,
such as BMI, physical activity, and smoking.
Statistical Analyses
Descriptive statistics provide the mean, SD, count, percent-
age, and confidence interval (CI). Prepregnancy, pregnancy,
and 6-month postpregnancy characteristics were evaluated
for their association with time to subsequent hypertension
using hazard ratios (HRs) and 95% CIs obtained from Cox
proportional hazard analyses. Two models were used in the
evaluation of pregnancy-related risk factors for their associ-
ation with subsequent hypertension. Model 1 adjusted for
maternal age (years) at delivery. Model 2 adjusted for
maternal age and prepregnancy risk factors, including the
following: BMI (kg/m2), educational level (primary, sec-
ondary/vocational, and any college/university), physical
activity (<3 and ≥3 times/wk), daily smoking (yes versus
no), alcohol consumption frequency (less than monthly,
monthly, or weekly), and duration of lifetime oral contracep-
tive use (none, <4 years, and ≥4 years). Other risk factors
that were adjusted for included midpregnancy poor diet
quality (yes versus no) and total energy intake (kcal/d) and
multiple birth pregnancies at delivery.
We evaluated the possibility of effect modification between
PE/GH (yes versus no) and gestational age (very preterm,
<32 weeks; moderately preterm, 32–36 weeks; and term)
and between PE/GH and weight-for-gestational age and sex
categories (very small, <2.5%; moderate, 2.5%–9.9%; and
average, ≥10%) in age-adjusted analyses (Table S1). No
significant interactions were noted. The presence of a PE/GH
with a very preterm delivery (gestational week, <32) was
associated with the highest age-adjusted HR for subsequent
hypertension when compared with term deliveries without
PE/GH (Table S1). The small sample size with this combina-
tion resulted in overlapping 95% CIs with other risk groups
and a nonsignificant (PE/GH9preterm) interaction term.
There was no evidence of interaction between PE/GH and
SGA (Table S1) or between SGA and preterm delivery (data
not shown). Also, there was no interaction between PE/GH
and large for gestational age (LGA; data not shown).
Given that PE/GH associates with the other pregnancy-
related events, PE/GH was added as a covariate to model 2
when evaluating DM/GDM, preterm delivery, and weight-for-
gestational age categories for their prediction of subsequent
hypertension.
For the analyses of the subgroup with available data
measured at 6 months postpartum, the follow-up time and
case counting started immediately at 6 months after delivery,
as opposed to 3 months after delivery. Models 1 and 2 were
repeated in the subgroup. An additional model was conducted
that included model 2 covariates plus daily breastfeeding (yes
versus no) and a high weight gain (≥7 versus <7 kg) at
6 months postpartum. The results of the analyses (models 1
and 2) in the subgroup with available 6 months postpartum
data were similar to the results based on the entire study
population. Furthermore, model 3 results were similar to
model 2 results. Therefore, results of the additional analyses
are not presented.
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Smoking at 6 months postpartum was also evaluated for
its association with subsequent hypertension in analyses
substituting it for the prepregnancy smoking variable and in
analyses evaluating combinations of prepregnancy and post-
pregnancy smoking and missing smoking data. Because
prepregnancy smoking and educational level were strongly
predictive of smoking at 6 months postpartum, additional
consideration of the postpartum smoking information did not
modify results.
The burden of hypertension detectable through pregnancy-
related events was estimated using the attributable fraction
(AF) method in STATA.39,40 The STATA punafcc calculates the
unattributable fraction, which, in the case of survival analyses,
represents the between-scenario HR where 2 scenarios are
possible: a theoretical counterfactual scenario where no one
has the risk factor in the population and the real-world
scenario where a percentage of the population has the risk
factor in question. The unattributable fraction is subtracted
from 1 to estimate the AF9100% (AF%) interpreted as the
burden of hypertension related to the unfavorable conditions
identified in pregnancy or at delivery.
Because pregnancy-related events are, to some degree,
interrelated, we also evaluated the cumulative percentage at
risk by sequentially adding pregnancy-related events, one at a
time, to the at-risk group. We then estimated the sequential
age- and multivariable-adjusted cumulative AF% on the basis
of the total percentage having ≥1 of the risk factors versus
none of the risk factors.41
We also conducted 3 sensitivity analyses to evaluate
consistencies in results: (1) restricted to women with a healthy
prepregnancy BMI (18.5–24.9 kg/m2); (2) restricted to nulli-
parous women at baseline, with a follow-up limited to the first
5 years after delivery; and (3) by age groups (<30, 30–34, 35–
39, and with too few ≥40 years for analyses; n=1382). Finally,
we also evaluated the extent to which HRs varied with
sequentially greater lengths of follow-up given that the
Schoenfeld test indicated deviations in proportionality of HR
for some, but not all, of the pregnancy-related characteristics.42
Statistical significance was determined by P≤0.05. Stata 14
(Stata Corp LP, College Station, TX) was used in the analyses.
Results
The mean (SD) age of participants at childbirth was 30.5 (4.6)
years, and the mean length of follow-up was 7.1 (1.6) years,
with a maximum follow-up of 10 years. Before pregnancy,
21.7% were overweight and 9.5% were obese; 16.5% smoked
daily, with a mean (SD) of 11 (5.9) cigarettes/d; and 47.9%
engaged in leisure-time physical activity ≥3 times per week
(Table 1). On the basis of questions about mothers’ parents’
native language, 9% of the study participants had either a
mother or father who was not ethnic Norwegian. At 6 months
postpartum, 80% reported daily breastfeeding, and 10%
reported a weight gain of ≥7 kg compared with prepregnancy
weight. The mean (SD) weight gain was 1.16 (4.6) kg.
A total of 1480 women developed pharmacologically
treated hypertension within the follow-up among the 60 027
women who contributed 412 518 total person-years of
observation (ie, rate of subsequent hypertension, 3.6/
1000 person-years). The estimated median duration of anti-
hypertensive use based on number of dispensed medication
episodes was 24 months (interquartile range, 9–48 months),
with increasing duration of use noted with increasing years of
follow-up.
In maternal age-adjusted analyses (model 1), a greater risk
of subsequent hypertension was predicted by an overweight
and obese prepregnancy BMI, prepregnancy daily smoking,
low educational level (primary or secondary), poor diet quality,
low physical activity level, and high weight retention at
6 months postpartum relative to the respective comparison
groups (data not shown). Occasional and weekly alcohol
consumption, a greater duration of oral contraceptive use
before index pregnancy, and breastfeeding daily at 6 months
associated with reduced risk of hypertension compared with
their respective comparison groups. A parity of ≥2 before the
MoBa registered pregnancy was associated with a maternal
age-adjusted HR (95% CI) for subsequent hypertension of 1.45
(1.26–1.66), whereas a parity of 1 was not significantly
Table 1. Baseline Prepregnancy and 6 Months Postpartum
Characteristics: MoBa Cohort Study (60 027 Women With
Deliveries in 2004–2009 in Norway)
Characteristics Values
Maternal age at delivery, mean (SD), y 30.5 (4.6)
Norwegian ethnicity, % 91.1
Prepregnancy body mass index, mean (SD), kg/m2 24.0 (4.3)
Prepregnant overweight (25.0–29.9 kg/m2), % 21.7
Prepregnant obese (≥30 kg/m2), % 9.5
Any college/university, % 28.1
Weekly alcohol consumption, % 28.2
Daily smoking, % 16.5
Physical activity ≥3 times/wk, % 47.9
Poor diet quality, %* 42.7
Oral contraceptive use history ≥4 y, % 53.3
Weight gain >7 kg, %† 10.0
Breastfeeding daily, %‡ 80.3
MoBa indicates Norwegian Mother and Child Cohort Study.
*A high sodium/potassium ratio in the top quartile (≥0.88) or a low dietary calcium or
magnesium intake (<736 or <310 mg/d, respectively).
†At 6 months postpartum relative to prepregnancy weight.
‡At 6 months postpartum.
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associated with risk (HR, 1.07; 95% CI, 0.94–1.21) relative to
nulliparity at baseline (data not shown).
During pregnancy, a total of 3381 women developed either
PE or GH, of whom 1235 had GH, 1642 had term PE, and 504
had preterm PE (defined as a PE delivery before gestational
week 37). There were 46 women with eclampsia in the PE
group.
In age-adjusted analyses (model 1), PE (HR, 7.67; 95% CI,
6.69–8.80) and GH (HR, 8.93; 95% CI, 7.61–10.49) had
similar HRs for subsequent hypertension averaged over the
entire follow-up (Table 2). In age-adjusted analyses, DM/
GDM, preterm delivery, particularly early preterm delivery,
very SGA (<2.5 birth weight percentile), and LGA (>90 birth
weight percentile) were also significantly associated with
increased risk of subsequent hypertension (Table 2).
In evaluation of combinations of pregnancy-related
complications, the presence of a PE/GH with a very
preterm delivery (gestational week <32) was associated
with the highest HR for subsequent hypertension (age-
adjusted HR of 14.33; 95% CI, 9.03–22.70) when compared
with term deliveries without PE/GH (Table S1). However,
the small sample size with this combination resulted in
overlapping 95% CIs with other risk groups and a
nonsignificant (PE/GH9preterm) interaction term. There
was no evidence of interaction between PE/GH and SGA
(Table S1) or between SGA and preterm delivery (data not
shown). Also, there was no interaction between PE/GH and
LGA (data not shown).
In model 2 analyses, there was only a modest attenuation
in the HRs associated with PE and GH (Table 2). Also, DM/
GDM and preterm delivery persisted as being significantly
associated with subsequent hypertension, although there was
a marked attenuation in the multivariable-adjusted HRs
observed. In contrast, SGA, including very SGA, and LGA
were no longer significantly associated with increased risk of
subsequent hypertension in multivariable models.
Table 2. HRs (95% CIs) of Pharmacologically Treated Hypertension Within 10 Years After Delivery With Respect to Pregnancy-
Related Risk Factors: MoBa Cohort Study (60 027 Women With Deliveries in 2004–2009 in Norway)
Risk Factors N Cases* Model 1† Model 2‡
De novo hypertensive disorders of pregnancy
None 56 646 1039 1.00 (Reference) 1.00 (Reference)
PE 2146 266 7.67 (6.69–8.80) 6.00 (5.15–6.99)
GH 1235 175 8.93 (7.61–10.49) 7.13 (5.93–8.58)
DM/GDM§
No 59 100 1391 1.00 (Reference) 1.00 (Reference)
Yes 927 89 4.08 (3.29–5.06) 2.43 (1.91–3.10)
Preterm delivery§
No 56 466 1301 1.00 (Reference) 1.00 (Reference)
Yes (<37 wk) 3298 170 2.25 (1.92–2.64) 1.45 (1.19–1.76)
<32 wk 447 36 3.58 (2.55–5.03) 2.10 (1.44–3.06)
32–36 wk 2851 134 2.04 (1.70–2.44) 1.35 (1.09–1.66)
Weight-for-gestational age§,k
All small (<10%) 4232 111 1.15 (0.95–1.40) 1.12 (0.90–1.39)
<2.5% 854 30 1.50 (1.05–2.16) 0.81 (0.53–1.24)
2.5%–9.9% 3378 81 1.06 (0.84–1.33) 1.07 (0.84–1.38)
Average (10%–90%) 48 875 1146 1.00 (Reference) 1.00 (Reference)
Large (>90%) 6624 214 1.29 (1.12–1.49) 0.94 (0.81–1.11)
CI indicates confidence interval; DM/GDM, pregestational and gestational diabetes mellitus or type not specified; GH, gestational hypertension; HR, hazard ratio; MoBa, Norwegian Mother
and Child Cohort Study; and PE, preeclampsia/eclampsia.
*Identified through antihypertensive medications dispensed after pregnancy, where hypertension is listed as indication for treatment. When medication dispensed only during the
postpartum period of <3 months, individuals were coded normotensive.
†Adjusted for maternal age (years).
‡Adjusted for maternal age (years), prepregnancy body mass index (kg/m2), educational level (primary, secondary/vocational, and any college/university), physical activity (<3 and ≥3
times/wk), daily smoking (yes vs no), alcohol consumption frequency (less than monthly, monthly, or weekly), duration of prepregnancy oral contraceptive use (never, <4 years, or ≥4
years), poor diet quality (yes vs no), energy intake (kcal/d), and multiple birth pregnancy.
§Additional adjustment for PE/GH included in model 2.
kUsing national birth weight by gestational age and sex growth curves.38
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In the analyses restricted to women with a healthy prepreg-
nancy BMI (18.5–24.9 kg/m2), slightly greater HRs were
observed for the pregnancy-related risk factors than those
observed in the primary analyses (Table S2). Furthermore,
greater HRs were associated with the pregnancy-related risk
factors in the analyses restricted to nulliparous women within
the first 5 years of follow-up than in the primary analyses
(Table S3). In contrast, SGA and LGA were not associated with
subsequent hypertension risk in the 2 sensitivity analyses,
similar to the overall findings (Tables S2 and S3). Finally, in
age-stratified analyses, we found homogeneous HRs and
overlapping 95% CIs for all pregnancy-related risk factors by
age group examined and, because results were comparable to
those presented in Table 2, they are not separately
presented.
HRs by Length of Follow-Up
The HRs for subsequent hypertension associated with having
PE/GH and preterm delivery decreased over greater lengths
of follow-up, whereas the HRs associated with having DM/
GDM remained stable over time (Table S4).
Burden of Hypertension Assessed Via AFs
In age-adjusted analyses, the AF%s associated individually
with PE (15.3%), GH (10.2%), DM/GDM (4.5%), and preterm
delivery (6.5%) provided a cumulative percentage at risk of
11.4%, corresponding to a combined at-risk group HR of 5.0
(95% CI, 4.5–5.6). This resulted in a cumulative AF% of 30.3%
(95% CI, 27.6%–33.1%) (Table 3). In analyses adjusting for
model 2 covariates, the cumulative AF% was only modestly
reduced to 28.6% (95% CI, 25.5%–31.6%). In the sensitivity
analyses restricted to women with a normal prepregnancy
BMI (18.5–25.9 kg/m2), we observed similar results, where
9.4% had ≥1 risk factor that contributed to a cumulative
multivariable-adjusted AF% of 25.9% (95% CI, 21.3%–30.3%).
For nulliparous women, 14.4% had ≥1 pregnancy-related risk
factors, with a combined at-risk group HR of 7.3 (95% CI, 5.9–
9.1), which corresponded to a cumulative multivariable-
adjusted AF% of 46.4% (95% CI, 39.1%–52.7%) in analyses
restricted to the first 5 years of follow-up. A large proportion
Table 3. AFs and Cumulative AFs (95% CIs) for Pharmacologically Treated Hypertension by Pregnancy-Related Risk Factors: MoBa
Cohort (60 027 Women With Deliveries in 2004–2009 in Norway)*









Total study sample (1480 cases among 60 027 women)
PE 3.6 15.3 (13.3–17.3) 3.6 15.3 (13.3–17.3) 14.7 (12.5–16.9)
GH 2.1 10.2 (8.5–11.9) 5.6 26.1 (23.7–28.5) 25.3 (22.6–27.9)
DM/GDM 1.5 4.5 (3.3–5.8) 7.0 28.8 (26.3–31.3) 27.5 (24.7–30.3)
Preterm delivery 5.5 6.5 (4.7–8.2) 11.4 30.4 (27.6–33.1) 28.6 (25.5–31.6)
Normal body mass index (≥18.5 to < 25) (549 cases among 38 559 women)k
PE 2.7 11.9 (8.9–14.8) 2.7 11.9 (8.9–14.8) 12.8 (9.6–16.0)
GH 1.6 10.8 (8.0–13.5) 4.3 23.2 (19.3–26.9) 23.8 (19.7–27.7)
DM/GDM 0.9 2.6 (1.0–4.1) 5.1 24.0 (20.0–27.8) 24.5 (20.3–28.7)
Preterm delivery 5.2 5.1 (2.4–7.7) 9.4 25.0 (20.6–29.0) 25.9 (21.3–30.3)
Follow-up <5 y for nulliparous women at baseline (327 cases among 26 023 women)
PE 5.2 29.2 (23.7–34.3) 5.2 29.2 (23.7–34.3) 28.4 (22.4–33.9)
GH 2.7 11.0 (7.1–14.7) 7.9 41.7 (35.6–47.2) 41.0 (34.4–47.0)
DM/GDM 1.5 5.8 (2.9–8.6) 9.3 45.8 (39.6–51.5) 44.6 (37.8–50.7)
Preterm delivery 6.7 11.4 (6.9–15.7) 14.4 47.5 (40.9–53.4) 46.4 (39.1–52.7)
AF indicates attributable fraction; CI, confidence interval; DM/GDM, pregestational and gestational diabetes mellitus or type not specified; GH, gestational hypertension; MoBa, Norwegian
Mother and Child Cohort Study; and PE, preeclampsia/eclampsia.
*Identified through antihypertensive medications dispensed after pregnancy, where hypertension was listed as indication for treatment. When medication dispensed only during the
postpartum period of <3 months, individuals were coded normotensive.
†Because risk factors are interrelated, the cumulative percentage at risk does not equal the addition of the individual percentage with each risk factor.
‡Cumulative age-adjusted AFs based on sequential population AFs using method described elsewhere.40
§Cumulative AFs adjusted for maternal age (years), prepregnancy body mass index (kg/m2), educational level (primary, secondary/vocational, and any college/university), physical activity
(<3 and ≥3 times/wk), daily smoking (yes vs no), alcohol consumption frequency (less than monthly, monthly, or weekly), duration of prepregnancy oral contraceptive use (never, <4 years,
or ≥4 years), poor diet quality (yes vs no), energy intake (kcal/d), and multiple birth pregnancy.
kPregnancy body mass index (kg/m2) removed from model 2.
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of the cumulative AF%s was attributed to the effect associated
with PE/GH. However, in analyses of nulliparous women
restricted to the first 5 years after delivery, DM/GDM and
preterm delivery contributed more to the cumulative AF% than
in the other analyses.
Discussion
We found persistent excess risk of hypertension after
pregnancy within 10 years after PE/GH, DM/GDM, and
preterm delivery after adjusting for numerous covariates.
However, we found no evidence that SGA or very SGA
associated with increased hypertension risk independent of
PE/GH. Furthermore, the AF% provides another quantitative
perspective of the value of pregnancy events beyond that of
the HR, indicating the proportion of at-risk hypertensive
women who would be identified by women’s reproductive
histories early in the disease trajectory. Hypertension is an
important and modifiable intermediary between pregnancy-
related events and future cardiovascular morbidity and
mortality. Although there are common antecedents between
pregnancy complications and CVD, our analyses indicated
that, after adjustment for numerous prepregnancy and 6-
month postpartum risk factors, the increased risk for
subsequent hypertension within 10 years after a pregnancy
complicated by PE/GH, DM/GDM, and/or preterm delivery
persisted.
Furthermore, in analyses restricted to women with a
healthy prepregnancy BMI, we found a similar magnitude in
the HRs and the AF%s as those observed for the total study
population. The results provide further evidence that preg-
nancy is a “stress test” for long-term maternal health and
disease,43 even in low-risk women with a healthy prepreg-
nancy weight.
For preterm delivery, we observed an attenuation in the
age-adjusted HR for subsequent hypertension of 2.0 to 1.45
after adjustment for multiple covariates. The results of the
current study are similar to findings from a study evaluating
preterm delivery and subsequent CVD in the NHS (Nurses’
Health Study), where a multivariable-adjusted HR of 1.4 was
identified for preterm delivery.11 We also observed a high HR
associated with having PE/GH and a very preterm delivery
(<32 weeks’ gestation), findings that corroborate several
previous studies that lacked adjustment for many of the
covariates included in the current study.
The observed age-adjusted association between having
delivered an LGA infant and subsequent hypertension
became nonsignificant in multivariable analyses. For
associations between high birth weights and future mater-
nal CVD risk, maternal obesity and issues related to
glycemic control are likely important mediators of long-term
risks.7,44
An important finding of our study is the lack of an
association between SGA and very SGA and subsequent
hypertension independent of PE/GH or preterm delivery, and
lack of evidence of interaction between SGA and preterm
delivery or between SGA and PE/GH. SGA deliveries repre-
sent diverse situations, including constitutionally small but
healthy births to constitutionally small but healthy mothers as
well as placental dysfunction, with various underlying causes,
including smoking (the latter associating with lower rates of
PE). Therefore, the implications of SGA may vary between
diverse study populations and by the ability to adjust for
important covariates, such as smoking or mother’s BMI.
Another inherent problem about the use of birth-weight-by-
gestational age and sex percentiles, particularly for low
gestational ages, is the bias introduced by not being able to
account for the fetal weights of unborn fetuses that continue
to mature until delivery, resulting in SGA infants that are
preterm likely being more growth restricted than their birth
weight percentiles indicate. Although we did observe a 50%
elevated risk of subsequent hypertension among women who
delivered a very SGA infant in age-adjusted analyses, the
excess risk did not persist in multivariable analyses. Several
studies indicate that an SGA or low birth weight associated
with higher subsequent maternal blood pressure20,44 or
CVD.7,45,46 In a predominantly Swedish study population,
with only 10.3% immigrants from non-Nordic countries, very
SGA (<2 SDs) was associated with a 60% greater CVD risk
compared with a birth weight percentile within 1 SDs in
analyses adjusting for smoking, socioeconomic status, and
other covariates.7 Also, the Swedish study observed signifi-
cant associations between very SGA and early preterm
deliveries with CVD.7 However, in our analyses including
additional covariates, we found no evidence that SGA or very
SGA predicted subsequent hypertension independent of PE/
GH or preterm delivery. In 6000 women in the National Health
and Nutrition Examination Survey, preterm SGA was a
significant predictor of hypertension only in non-Hispanic
blacks.47 It is postulated that the more severe the placental
dysfunction, the higher the risk for maternal premature
CVD.48 Our SGA results may relate, in part, to having more
healthy study participants than the general population; our
rates of SGA and very SGA were lower than anticipated (7.1%
and 1.4% versus the expected 10% and 2.5%, respectively).
Because risk factors can change over time and because
the first pregnancy may represent the optimal stress test for
future maternal health, we conducted sensitivity analyses
limited to nulliparous women within the first 5 years of follow-
up, in which we observed stronger associations between PE/
GH, DM/GDM, and preterm delivery with subsequent hyper-
tension.
In a previous study based on record linkages in Norway,
HRs for hypertension associated with PE decreased as the
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duration of follow-up increased.49 Also, a meta-analysis
identified greater HRs for heart failure, stroke, and CVD
deaths during the first 10 years after a pregnancy affected by
PE compared with that beyond 10 years.50 Our higher HRs for
subsequent hypertension associated with PE/GH than those
observed in the prevailing literature of long-term CVD
outcomes may be attributed to hypertension being a modi-
fiable intermediary of CVD and to our shorter length of follow-
up in a young population. With increasing age, there is an
increasing hypertension and CVD occurrence in women
without a history of pregnancy-related events.
In the Netherlands component of the EPIC (European
Prospective Investigation Into Cancer and Nutrition), hyper-
tension and type 2 DM fully accounted for the association
between self-reported hypertension in a prior pregnancy and
later-life CVD.22 The excess risk of future CVD associated with
pregnancy-related events could, theoretically, be mitigated by
early detection, preventive action, and pharmacological
treatment.
Strengths and Limitations
Strengths of the current study involve the availability of a wide
range of important prepregnancy risk factors and weight gain
and breastfeeding status at 6 months postpartum. Further-
more, the sample size of >60 000 women enabled us to
conduct sensitivity analyses limited to relevant subgroups.
Limitations include the lack of information about family
history of disease and maternal hyperlipidemia before or after
pregnancy. The ethnically homogeneous study population
prevents generalizability to more ethnically diverse popula-
tions. Also, because of the small number of women ≥40 years
of age in the current study, the results may not be
generalizable to older women. Another limitation is a likely
underascertainment of GDM in the MBRN. Therefore, our
ability to evaluate the implications of GDM for future
hypertension risk is limited in the current research material.
GDM, however, is already an established precursor to DM,
which, in turn, is an established risk factor for CVD.51 Another
limitation is that we anticipate some underreporting of milder
PE/GH in the MBRN, and this would result in an underascer-
tainment of the true burden of subsequent hypertension
associated with PE/GH. Furthermore, we were not able to
evaluate participants’ entire reproductive histories in the
current analyses. Nonetheless, the magnitude of the HRs
observed in the current report is similar to many studies on
this topic in which a full reproductive history has been
available. Finally, the low participation rate in MoBa (41%)
raises questions of generalizability. However, in an evaluation
of the potential for selection bias in the MoBa, no differences
were noted in 8 exposure-outcome associations comparing
results obtained from the MoBa study population with that
obtained from the MBRN.52 Furthermore, in all births
registered in the MBRN (2004–2009), we observed similar
percentages of births affected by PE (3.6%), GH (1.9%), DM/
GDM (2.0%), and preterm delivery (6.3%) (http://www.fhi.no)
as in our selected MoBa cohort of women who were
normotensive before index pregnancy. The similar prevalence
in these events in the MoBa and the national population-
based register suggests that the AF%s derived from the MoBa
cohort are likely reasonable estimates of the AF%s for the
general population.
Summary
Our finding of several pregnancy complications predicting
development of premature hypertension, particularly after the
first pregnancy, suggests the first postpartum assessment of
women46 would be an ideal time for triaging for high
premature maternal CVD risk. A 6- to 12-week postpartum
assessment, routinely offered in many high-income countries,
could be an ideal time for physicians to identify and offer high-
risk women at a young age enhanced monitoring and
interventions. Pregnancy histories can optimize maternal
cardiovascular health and reduce the burden of premature
CVD disease for women.
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Table S1. Hazard ratios (95% CI) of pharmacologically-treated hypertension* by preeclampsia/eclampsia and gestational hypertension 
stratified by gestational age and weight-for-gestational age categories: MoBa Cohort Study (60,027 women with deliveries 2004-2009 in 
Norway). 
 
 Preeclampsia/eclampsia or gestational hypertension 
 Yes No 
 
Risk Factor N Cases Model 1† Model 2‡ 
 
N Cases Model 1† Model 2‡ 
 
Gestational age (weeks) 
 
        
   < 32  106 22 14.33 (9.03-22.70) 12.68 (7.70-20.89) 341 14 2.27 (1.33-3.85) 2.15 (1.24- 3.74) 
 
   32 – 36  490 72   9.25 (7.22-11.86)   7.94 (5.97-10.56) 2,361 62 1.45 (1.12-1.87) 1.42 (1.07-1.88) 
 
   > 37  2,766 345   8.01 (7.08-9.06)   6.19 (5.38-7.13) 53,700 956 1.00 (reference) 1.00 (reference) 
         
Weight-for-gestational age categories§ 
 
     
  < 2.5%  159 18   6.69 (4.19-10.70)   5.26 (3.03-9.13) 695 12 0.93 (0.53-1.63) 0.80 (0.41-1.55) 
 
  2.5 – 9.9% 392 45   6.91 (5.11-9.37)   6.14 (4.42-8.52) 2,986 36 0.68 (0.48-0.94) 0.67 (0.46-0.98) 
 
  > 10% 2,811 376   8.24 (7.31-9.29)   6.38 (5.56-7.31) 52,688 984 1.00 (reference) 1.00 (reference) 
         
CI indicates confidence interval. 






* Identified through antihypertensive medications dispensed following pregnancy where hypertension listed as indication for treatment. When 
medication dispensed only during the post-partum period of < 3 months individuals were coded normotensive.  
†Adjusted for maternal age (yrs).  
‡Adjusted for maternal age (yrs), prepregnancy body mass index (kg/m2), educational level (primary, secondary/vocational, and any 
college/university), physical activity (<3 times, and 3 or more times/week), daily smoking (yes v. no), alcohol consumption frequency (less than 
monthly, monthly, weekly), duration of prepregnancy oral contraceptive use (never, < 4 years, 4 or more years), poor diet quality (yes v. no), 
energy intake (Kcal/d), and multiple birth pregnancy.   
§Using national birth weight by gestational age and sex growth curves (very small, < 2.5%, moderate small 2.5-9.9%, and not small > 10%).1 







Table S2. Pregnancy-related events hazard ratios (95% CI) for pharmacologically-
treated hypertension* within 10 years following delivery among women with a healthy 
prepregnancy body mass index: MoBa Cohort Study (38,559 women with deliveries 
2004-2009 in Norway).  
 Women with prepregnant body mass index 18.5 – 24.9 kg/m2 
 
Risk Factor N Cases* Model 1† 
 
         Model 2‡ 
De novo hypertensive disorders of pregnancy 
 
  None 36,908 406 1.00 (reference)     1.00 (reference) 
  PE 1,037 77 7.61 (5.95-9.74) 8.40  (6.49-10.88) 
  GH 614 66 11.55 (8.90-14.98) 12.07 (9.09-16.03) 
DM/GDM      
  No 38,200 530 1.00 (reference) 1.00 (reference) 
  Yes 359 19 3.89 (2.47-6.15) 3.36 (2.05-5.51) 
Preterm delivery     
  No 36,410 490 1.00 (reference) 1.00 (reference) 
  Yes (<37 weeks) 1,983 55 2.05 (1.55-2.71) 2.19 (1.59-3.02) 
       < 32 weeks 263 9 2.49 (1.28-4.83) 2.64 (1.28-5.47) 
       32-36 weeks 1,720 46 2.00 (1.48-2.71) 2.15 (1.53-3.01) 
Weight-for-gestational age and sex§ 
  All small (<10%) 2,902 44 1.14 (0.83-1.55) 0.70 (0.48-1.00) 
       <2.5% 569 14 1.82 (1.07-3.09) 0.92 (0.50-1.66) 
       2.5-9.9% 2,333 30 0.97 (0.67-1.40) 0.62 (0.40-0.95) 
  Average (10-90%) 32,078 440 1.00 (reference) 1.00 (reference) 
  Large (>90%) 3,392 61 1.24 (0.95-1.62) 1.01 (0.74-1.37) 







CI indicates confidence interval; PE, preeclampsia/eclampsia; GH, gestational hypertension; 
DM/GDM, pregestational and gestational diabetes mellitus or type not specified. 
*Identified through antihypertensive medications dispensed following pregnancy where 
hypertension listed as indication for treatment. When medication dispensed only during the 
post-partum period of < 3 months individuals were coded normotensive. 
†Adjusted for maternal age.  
‡Adjusted for maternal age, prepregnancy body mass index (kg/m2), educational level 
(primary, secondary/vocational, and any college/university), physical activity (<3 times, and 3 
or more times/week), daily smoking (yes v. no), alcohol consumption frequency (less than 
monthly, monthly, weekly), duration of prepregnancy oral contraceptive use (never, < 4 years, 
4 or more years), and a low dietary intake of minerals (yes v. no), energy intake (Kcal/d), and 
multiple birth pregnancy.  For all non-hypertensive pregnancy risk factors, adjusts for 
hypertensive disorders of pregnancy.   
§Using national birth weight by gestational age and sex growth curves.1 
  







Table S3. Pregnancy-related event hazard ratios (95% CI) for pharmacologically-
treated hypertension* within 5 years following delivery in nulliparous women at 
baseline: MoBa Cohort Study (26,023 women with deliveries 2004-2009 in Norway).  
  Follow-up < 5 years for nulliparous women at baseline 
 







De novo hypertensive disorders of pregnancy 
 
  None 23,964    176   1.00 (reference) 1.00 (reference) 
  PE   1,346 107   9.31 (7.39-11.72) 6.97 (5.31-9.14) 
  GH    713    44   5.50  (4.01-7.55) 4.31 (3.05-6.08) 
DM/GDM      
  No 25,625 303 1.00 (reference) 1.00 (reference) 
  Yes    398 24 4.87 (3.22-7.38) 3.22 (2.07-5.02) 
Preterm delivery     
  No 24,152 268 1.00 (reference) 1.00 (reference) 
  Yes (all <37 weeks) 1,726 57 2.93 (2.20-3.91) 1.88 (1.35-2.63) 
        < 32 weeks 265 15 5.03 (2.97-8.52) 2.62 (1.45-4.73) 
        32-36 weeks 1,461 42 2.55 (1.84-3.54) 1.73 (1.19-2.52) 
Weight-for-gestational age and sex§ 
 
  All small (< 10%)   2,644 42 1.26 (0.91-1.74) 0.92 (0.65-1.29) 
       <2.5% 548 12 1.71 (0.96-3.04) 0.89 (0.48-1.67) 
       2.5 – 9.9% 2,096 30 1.14 (0.78-1.66) 0.93 (0.67-1.37) 
  Average (10-90%)  21,507 263 1.00 (reference) 1.00 (reference) 
  Large (>90%) 1,714 20 0.97 (0.61-1.52) 0.60 (0.35-1.01) 
CI indicates confidence interval; PE, preeclampsia/eclampsia; GH, gestational hypertension; 
DM/GDM, pregestational and gestational diabetes mellitus or type not specified. 







*Identified through antihypertensive medications dispensed following pregnancy where 
hypertension listed as indication for treatment. When medication dispensed only during the 
post-partum period of < 3 months individuals were coded normotensive. 
†Adjusted for maternal age.  
‡Adjusted for maternal age, prepregnancy body mass index (kg/m2), educational level 
(primary, secondary/vocational, and any college/university), physical activity (<3 times, and 3 
or more times/week), daily smoking (yes v. no), alcohol consumption frequency (less than 
monthly, monthly, weekly), duration of prepregnancy oral contraceptive use (never, < 4 years, 
4 or more years), and a low dietary intake of minerals (yes v. no), energy intake 
(kilocalories/d), and multiple birth pregnancy.  For all non-hypertensive pregnancy risk 
factors, adjusts for hypertensive disorders of pregnancy.   
§Using national birth weight by gestational age and sex growth curves.1 
  







Table S4. Hazard ratios (95% CI) of pharmacologically-treated hypertension* with respect to pregnancy-related risk factors by 
sequentially longer lengths of follow-up: MoBa Cohort (60,027 women with deliveries 2004-2009 in Norway).   
 Length of follow-up  
 





    
    Model 1† 
 
11.39 (9.88-13.13) 9.26 (8.17-10.49) 8.38 (7.47-9.41) 8.13 (7.27-9.09) 
    Model 2‡ 
 
  9.40 (8.00-11.04) 7.45 (6.46-8.58) 6.62 (5.80-7.55) 6.38 (5.62-7.26) 
DM/GDM 
 
    
    Model 1† 
 
  4.34 (3.29-5.74) 4.23 (3.32-5.39) 4.22 (3.39-5.26) 4.08 (3.29-5.06) 
    Model 2‡,§ 
 
  2.45 (1.82-3.31) 2.43 (1.86-3.16) 2.44 (1.90-3.12) 2.43 (1.91-3.10) 
Preterm delivery‖ 
 
    
    Model 1† 
 
3.14 (2.59-3.81) 2.55 (2.13-3.04) 2.39 (2.03-2.81) 2.25 (1.92-2.64) 
    Model 2‡,§ 
 
1.89 (1.51-2.36) 1.60 (1.30-1.97) 1.56 (1.29-1.90) 1.45 (1.19-1.76) 
Combined group# 
 














    Model 2‡ 
 
5.94 (5.08-6.95) 4.77 (4.16-5.46) 4.36 (3.85-4.93) 4.17 (3.70-4.70) 
 







CI indicates confidence interval; PE, preeclampsia/eclampsia; GH, gestational hypertension; DM/GDM, pregestational and gestational diabetes 
mellitus or type not specified. 
*Identified through antihypertensive medications dispensed following pregnancy where hypertension listed as indication for treatment. When 
medication dispensed only during the post-partum period of < 3 months individuals were coded normotensive. 
†Adjusted for maternal age (yrs). 
‡Adjusted for maternal age, prepregnancy body mass index (kg/m2), educational level (primary, secondary/vocational, and any 
college/university), physical activity (<3 times, and 3 or more times/week), daily smoking (yes v. no), alcohol consumption frequency (less than 
monthly, monthly, weekly), duration of prepregnancy oral contraceptive use (never, < 4 years, 4 or more years), poor diet quality (yes v. no), 
energy intake (kilocalories/d), and multiple birth pregnancy. 
§Additional adjustment for PE/GH. 
‖ Less than 37 weeks gestational age. 
#Having one or more of the following:  PE/GH, DM/GDM, or preterm delivery. 
 









1. Skjaerven R, Gjessing HK, Bakketeig LS. Birthweight by gestational age in Norway. 
Acta Obstet Gynecol Scand. 2000;79:440-9.  
 






Kari Klungsøyr, Lill Trogstad, Per M. Magnus, Anne Lise Brantsæter and Margaretha Haugen
Grace M. Egeland, Svetlana Skurtveit, Anne Cathrine Staff, Geir Egil Eide, Anne-Kjersti Daltveit,
Cohort
Based Norwegian−Hypertension Within 10 Years of Delivery: Findings From a Population
 Related Risk Factors Are Associated With a Significant Burden of Treated−Pregnancy
Online ISSN: 2047-9980 
Dallas, TX 75231
 is published by the American Heart Association, 7272 Greenville Avenue,Journal of the American Heart AssociationThe 
doi: 10.1161/JAHA.117.008318
2018;7:e008318; originally published May 13, 2018;J Am Heart Assoc. 
 http://jaha.ahajournals.org/content/7/10/e008318
World Wide Web at: 
The online version of this article, along with updated information and services, is located on the
 
 for more information. http://jaha.ahajournals.orgAccess publication. Visit the Journal at 
 is an online only OpenJournal of the American Heart AssociationSubscriptions, Permissions, and Reprints: The 
 by guest on June 8, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
